Freeline Therapeutics Holdings Equity 2024

Freeline Therapeutics Holdings Aktienanalyse

What does Freeline Therapeutics Holdings do?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Freeline Therapeutics Holdings's Equity

Freeline Therapeutics Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Freeline Therapeutics Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Freeline Therapeutics Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Freeline Therapeutics Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Freeline Therapeutics Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Freeline Therapeutics Holdings Stock

What is the equity of Freeline Therapeutics Holdings this year?

Freeline Therapeutics Holdings has equity of 52.4 M USD this year.

What was the equity of Freeline Therapeutics Holdings compared to the previous year?

The equity of Freeline Therapeutics Holdings has increased/decreased by -56.48% decreased compared to the previous year.

What impact does a high equity have on investors of Freeline Therapeutics Holdings?

A high equity is advantageous for investors of Freeline Therapeutics Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Freeline Therapeutics Holdings?

A low equity can be a risk for investors of Freeline Therapeutics Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Freeline Therapeutics Holdings affect the company?

An increase in equity of Freeline Therapeutics Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Freeline Therapeutics Holdings affect the company?

A reduction in equity of Freeline Therapeutics Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Freeline Therapeutics Holdings?

Some factors that can affect the equity of Freeline Therapeutics Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Freeline Therapeutics Holdings so important for investors?

The equity of Freeline Therapeutics Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Freeline Therapeutics Holdings take to change the equity?

To change equity, Freeline Therapeutics Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Freeline Therapeutics Holdings pay?

Over the past 12 months, Freeline Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Freeline Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Freeline Therapeutics Holdings?

The current dividend yield of Freeline Therapeutics Holdings is .

When does Freeline Therapeutics Holdings pay dividends?

Freeline Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Freeline Therapeutics Holdings?

Freeline Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Freeline Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Freeline Therapeutics Holdings located?

Freeline Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Freeline Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Freeline Therapeutics Holdings from 7/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Freeline Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Freeline Therapeutics Holdings in the year 2023?

In the year 2023, Freeline Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Freeline Therapeutics Holdings pay out the dividend?

The dividends of Freeline Therapeutics Holdings are distributed in USD.